UniProt P29322 · PDB · AlphaFold · Substrate: pEY · Clone: catalytic domain (aa 565-1005)medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 98.5% | 1.5% | 87.22 | 0.555 |
| 2 | Dasatinib | 97.6% | 2.4% | 87.97 | 0.699 |
| 3 | Ponatinib | 97.0% | 3.0% | 78.23 | 0.534 |
| 4 | Nilotinib | 77.5% | 22.5% | 96.49 | 0.765 |
| 5 | Vandetanib | 76.0% | 24.0% | 95.74 | 0.723 |
| 6 | Ripretinib | 70.4% | 29.6% | 92.95 | 0.674 |
| 7 | Repotrectinib | 69.9% | 30.1% | 84.21 | 0.608 |
| 8 | Cabozantinib | 64.4% | 35.6% | 92.73 | 0.751 |
| 9 | Crizotinib | 46.4% | 53.6% | 91.39 | 0.581 |
| 10 | Tivozanib | 44.3% | 55.7% | 92.42 | 0.673 |
| 11 | Canertinib | 26.3% | 73.7% | 96.49 | 0.671 |
| 12 | Erdafitinib | 23.6% | 76.4% | 95.71 | 0.737 |
| 13 | Gilteritinib | 21.0% | 79.0% | 88.97 | 0.506 |
| 14 | Apatinib | 19.8% | 80.2% | 97.73 | 0.704 |
| 15 | Umbralisib | 18.6% | 81.4% | 98.74 | 0.670 |
| 16 | Regorafenib | 18.0% | 82.0% | 95.99 | 0.719 |
| 17 | Pralsetinib | 16.8% | 83.2% | 93.43 | 0.643 |
| 18 | Ceritinib | 14.0% | 86.0% | 95.44 | 0.618 |
| 19 | Dacomitinib | 11.9% | 88.1% | 97.99 | 0.664 |
| 20 | Afatinib | 11.9% | 88.1% | 98.50 | 0.709 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.03
- Epithelial log2(TPM+1): 0.40
- Fold change: -0.37
- Status: No significant change
High-confidence drugs
- Dasatinib — inh 97.6% · KISS 39.71
- Bosutinib — inh 98.5% · KISS 33.72
- Ponatinib — inh 97.0% · KISS 29.15
Selectivity landscape vs inhibition on EPHA8
Each point is one of the 92 approved drugs; color = inhibition % on EPHA8.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…